Suppr超能文献

重组促红细胞生成素治疗对血液透析患者血清新蝶呤水平的影响。

Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects.

作者信息

Buemi M, Allegra A, Aloisi C, Frisina N

机构信息

Chair of Nephrology II, Messina University, Italy.

出版信息

Am J Nephrol. 1991;11(4):281-3. doi: 10.1159/000168322.

Abstract

The authors wished to investigate some aspects of the cell-mediated immunity in hemodialyzed subjects undergoing a treatment with recombinant erythropoietin (rHuEPO). The study was carried out through the dosage of the serum levels of neopterin, a substance produced by the macrophages and usable as a marker of their state of activation. The results show a significant reduction of the serum levels of pteridine already at the second month of treatment with rHuEPO (61 +/- 9 vs. 95 +/- 12 nmol/l), thus proving a probable inhibitory action carried out by erythropoietin on certain cells of the immune system.

摘要

作者希望研究接受重组促红细胞生成素(rHuEPO)治疗的血液透析患者细胞介导免疫的某些方面。该研究通过测定血清中新蝶呤的水平来进行,新蝶呤是一种由巨噬细胞产生的物质,可用作其激活状态的标志物。结果显示,在使用rHuEPO治疗的第二个月,血清蝶啶水平就显著降低(61±9 vs. 95±12 nmol/l),从而证明促红细胞生成素可能对免疫系统的某些细胞产生抑制作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验